BIOMX INC PHGE 深 滬
等待開盤 12-20 09:30:00 美东时间
2.13
+0.250
+13.30%
華盛通- 最 高2.2299
- 今 開1.86
- 成交量 9.32万股
- 最 低 1.86
- 昨 收 1.88
- 總市值 325.17万
- 52周最高 22.0571
- 市盈率 靜 --
- 換手率 6.11%
- 52周最低 1.5004
- 委 比 0.00%
- 總股本 152.66万
- 歷史最高 2261.00
- 量 比 0.91
- 振 幅 19.68%
- 歷史最低 1.86
- 每 手 1
- 風險率 3.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PHGE shares are trading lower after the company discontinued its Phase 2b trial of BX004 in cystic fibrosis patients with chronic Pseudomonas aeruginosa infections.
PHGE shares are trading lower after the company discontinued its Phase 2b trial...
12-08 20:41
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Praxis Precision Medicine (NASDAQ:PRAX) shares moved upwards by 33.6% ...
12-06 01:05
BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review
BiomX works to address FDA device questions as a safety panel supports the BX004 trial, with topline results now expected in Q2 2026.
11-27 02:23
Why Autodesk Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Shares of Autodesk Inc (NASDAQ:ADSK) rose sharply in pre-market trading after t...
11-26 17:33
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
11-26 10:07
BiomX Updates on Phase 2b Study for BX004
BiomX ( ($PHGE) ) has issued an announcement. On November 25, 2025, BiomX Inc. ...
11-26 06:26
HC Wainwright & Co. Maintains Buy on BiomX, Raises Price Target to $26
HC Wainwright & Co. analyst Joseph Pantginis maintains BiomX (AMEX:PHGE) with a Buy and raises the price target from $15 to $26.
11-25 19:54
BiomX announces 1-for-19 reverse stock split
BiomX (PHGE) on Friday said that it will implement a one-for-nineteen reverse split of its common shares, effective when trading opens on November 25 on a split-adjusted basis. The company said the mo...
11-15 05:37
BiomX Announces 1-For-19 Reverse Stock Split, Effective Nov. 25
BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it intends to
11-15 05:35
BiomX Q3 EPS $0.29 Beats $(0.32) Estimate
BiomX (AMEX:PHGE) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $(0.32) by 190.63 percent. This is a 193.55 percent increase over losses of $(0.31) per share from the same
11-12 20:32
